Predictors of All-Cause Mortality in Patients With Severe COPD and Major Depression Admitted to a Rehabilitation Hospital

Yohannes, Abebaw Mengistu; Raue, Patrick J.; Kanellopoulos, Dora; McGovern, Amanda R.; Sirey, Jo Anne; Kiosses, Dimitris N.; Banerjee, Samprit; Seirup, Joanna K.; Novitch, Richard S.; Alexopoulos, George S.

doi:10.1378/chest.15-0529

Cited by 28 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…68 Anxiety and depression contribute to the substantial burden of COPD-related morbidity and are associated with more impaired quality of life and reduced adherence to treatment. 69,70 Women with COPD report higher levels of anxiety and depression than men with COPD, furthering the burden of COPD in women. 56,66,[71][72][73] COPD exacerbations are associated with morbidity, mortality, resource burden, and health-care costs.…”

Section: Focusing On the Patient: How Does Copd Affect Women?mentioning

confidence: 99%

Improving the Management of COPD in Women

Jenkins

Chapman

Donohue

et al. 2017

CHEST

View full text Add to dashboard Cite

COPD is a highly debilitating disease that represents a substantial and growing health burden in women. There is increasing evidence for sex-related differences in COPD risk, progression, and outcomes. However, the disease receives scant attention as a women's health issue. Thus, a multifaceted approach is required to address COPD in women, including greater awareness, minimization of risk, and further elucidation of the sex-specific factors (biological and cultural) that affect risk, disease progression, and treatment success. This article reviews the current literature on the topic and provides suggestions for achieving better outcomes for the millions of women with COPD worldwide.

show abstract

Section: Focusing On the Patient: How Does Copd Affect Women?mentioning

confidence: 99%

Improving the Management of COPD in Women

Jenkins

Chapman

Donohue

et al. 2017

CHEST

View full text Add to dashboard Cite

show abstract

“…A study including stable patients with COPD even showed that drawing impairment predicted increased mortality risk [66]. Nevertheless, Yohannes et al found that MMSE scores did not predict 1-year all-cause mortality [67]. Moreover, only a modest association was found between executive function and survival in the NETT trial [65].…”

Section: Health Outcomesmentioning

confidence: 99%

Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions

Beers

Janssen

Gosker

et al. 2018

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Cognitive impairment (CI) is an important but an under-recognized extra-pulmonary feature of chronic obstructive pulmonary disease (COPD). It is related to the burden of disability, worse health outcomes, and impaired self-management. Areas covered: CI includes deterioration of a wide range of cognitive functions, such as memory and various executive functions. Risk of hospitalization might be higher in patients with COPD compared to those without, with CI negatively impacting the wellbeing of patients with COPD. Disease-specific factors such as hypoxemia and inflammation, lifestyle factors such as dietary insufficiencies and lack of physical activity, and comorbidities such as obstructive sleep apnea and depression are likely to synergistically contribute to the development of CI in COPD. Tailored interventions can possibly improve CI in COPD, but this needs further investigation. Expert commentary: Further research is warranted involving the optimization of neuropsychological testing for screening and outcome assessment, longitudinal studies to investigate the development of CI in COPD over time, and randomized clinical trials to test the feasibility and efficacy of promising interventions.

show abstract

“…Severe lung function impairment [10] High partial pressure of carbon dioxide [10] Severe dyspnoea [19] Impaired quality of life [11] Physical disability [11,19] Depression [11,13,16,22] Long-term oxygen therapy [11,14] Anxiety [16] Chronic heart failure [14,21] Falls and history of falls [19] Reduced exercise capacity [11]…”

Section: Clinically Relevant Markersmentioning

confidence: 99%

Serotonergic antidepressants in COPD: beneficial or harmful?

Yohannes

2018

Eur Respir J

Self Cite

View full text Add to dashboard Cite

@ERSpublications Antidepressants are associated with elevated risk of hospitalisation and mortality. This underscores that the importance of having a collaborative care and patient-centred approach to manage depression in patients with COPD is worthy of consideration.Chronic obstructive pulmonary disease (COPD) affects >174 million people and is now the third leading cause of death worldwide [1]. In 2011, in the European Union alone, the costs of COPD (including both direct and indirect costs, and lost productivity due to increased disability-adjusted life-years) exceed €141 billion [2, 3].Depression affects ∼40% of patients with COPD [4]. One in four individuals with COPD with depression will experience a chronic course of illness [5]. Inadequately treated depression is often associated with increased physical disability, impaired quality of life, social isolation, poor adherence to medical treatment, emergency healthcare utilisation, increased length of hospital stay and dependency on caregivers [4][5][6][7]. In addition, patients with COPD and concomitant major depression are disproportionately from a lower socioeconomic status, and exhibit higher rates of substance abuse disorders and significantly more comorbidities [4][5][6]. Depression in patients with COPD was associated with increases in both 30-and 60-day hospital readmission rates [8,9], and prior exacerbations predict both future exacerbations and an increased length of hospital stay [5,8,9]. In addition, factors associated with excessive mortality in patients with COPD include sociodemographic, behavioural and clinically relevant disease severity markers as shown in table 1 [10-21, 23, 24]. Eur Respir J 2018; 52: 1801095 | EDITORIAL COPD home residents newly starting SSRI/SNRI drugs compared to controls. In contrast, there was a significantly decreased rate of outpatient exacerbations among SSRI/SNRI users and no significant association with intensive care admissions during hospitalisations for COPD or pneumonia.

show abstract

Predictors of All-Cause Mortality in Patients With Severe COPD and Major Depression Admitted to a Rehabilitation Hospital

Abstract: BACKGROUND: COPD is a major cause of all-cause mortality. We examined predictors of 1-year mortality in patients with severe COPD and major depression after inpatient treatment in a rehabilitation hospital.

Cited by 28 publications

References 41 publications

Improving the Management of COPD in Women

Improving the Management of COPD in Women

Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions

Serotonergic antidepressants in COPD: beneficial or harmful?

Contact Info

Product

Resources

About